U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.30
    +0.48 (+0.57%)
     
  • Gold

    1,818.90
    +2.40 (+0.13%)
     
  • Silver

    23.03
    +0.12 (+0.51%)
     
  • EUR/USD

    1.1413
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3642
    -0.0038 (-0.28%)
     
  • USD/JPY

    114.5860
    +0.3860 (+0.34%)
     
  • BTC-USD

    42,284.47
    -726.00 (-1.69%)
     
  • CMC Crypto 200

    1,016.13
    -9.60 (-0.94%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

Clorox (CLX) Q1 Earnings and Sales Top Estimates, Decline Y/Y

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The Clorox Company CLX reported mixed results for first-quarter fiscal 2022, wherein the top and bottom lines beat the Zacks Consensus Estimate but declined year over year. Results were impacted by soft sales performance across two of the four segments. Lower shipment volume along with an unfavorable price mix mainly hurt sales. This along with higher manufacturing and logistics costs, and increased commodity costs dented the bottom line and margins.

Nonetheless, management is encouraged by the company’s portfolio, which helps it efficiently cater to the consumer demand and position it well for long-term growth. Its IGNITE strategy also appears encouraging.

Shares of the Zacks Rank #5 (Strong Sell) company have declined 0.4% in the past three months compared with the industry’s 2.8% fall.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Q1 Highlights

Adjusted earnings of $1.21 per share decreased 54% year over year but beat the Zacks Consensus Estimate of $1.01. The earnings decline can be attributed to a decrease in sales and a lower gross margin. Adjusted earnings excluded 7 cents related to investments in the company's long-term digital capabilities and productivity enhancements.

The company posted net sales of $1,806 million, beating the Zacks Consensus Estimate of $1,703 million. The top line, however, declined 6% from the year-ago quarter, whereas organic sales dipped 5%. Sales were mainly impacted by the decline of volume and unfavorable price mix. The adverse currency also hurt the top line by 1%. The company witnessed a 2% decline in volume and a 3% unfavorable price mix. However, it noted that sales increased 21% on a two-year basis.

The Clorox Company Price, Consensus and EPS Surprise

The Clorox Company Price, Consensus and EPS Surprise
The Clorox Company Price, Consensus and EPS Surprise

The Clorox Company price-consensus-eps-surprise-chart | The Clorox Company Quote

The gross margin contracted 1,090 basis points (bps) to 37% in the fiscal first quarter. Elevated manufacturing and logistics costs and higher commodity costs due to significant cost inflation hurt the gross margin.

Segmental Discussion

Sales of the Health and Wellness segment dropped 8% to $745 million on sales declines in two of the three business units. Lower shipment volume of professional products; vitamins, minerals and supplements; and unfavorable price mix led to the downside.

The Household segment’s sales declined 12% to $442 million, driven by sales declines in two of the three business units — Bags & Wraps, and Grilling. Unfavorable price mix; lower shipments in Grilling and Bags & Wraps; and unfavorable price mix were the primary reasons.

Sales at the Lifestyle segment improved 4% year over year to $331 million. Growth in two of the three businesses due to higher volume from increased shipments Water Filtration and Natural Personal Care aided the segment’s sales. This was partly negated by the unfavorable price mix.

In the International segment, sales rose 1% to $288 million from the year-ago quarter on a favorable price mix, offset by a slight decline in shipment volume and unfavorable currency. Organic sales for the segment improved 3%.

Financials

Clorox ended first-quarter fiscal 2022 with cash and cash equivalents of $210 million, and long-term debt of $1,885 million. In the fiscal first quarter, the company generated $41 million of net cash from operations.

Fiscal 2022 Guidance

Management notes that fiscal 2022 started on a strong note. It witnessed a better-than-anticipated demand across its portfolio despite the tough environment. The company reiterated its fiscal 2022 outlook. It envisions a 2-6% sales decline, both on a reported and organic basis, for fiscal 2022.

The gross margin is expected to decline 300-400 bps in fiscal 2022 on escalated commodity costs, and manufacturing and logistics expenses, particularly transportation. The company expects to return to gross margin growth in the fourth quarter of fiscal 2022.

Selling and administrative expenses, as a percentage of sales, are projected to be 15% of sales. The company anticipates 1% of this to be for planned investments in digital capabilities and productivity enhancements. It expects advertising and sales promotion expenses to be 10% of net sales. The higher spending mainly relates to an increase in brand investments to support its innovation pipeline and customer engagement efforts. The effective tax rate is anticipated at 22-23%.

Consequently, adjusted earnings for fiscal 2022 are estimated to be $5.40-$5.70 per share, suggesting a year-over-year decline of 26-21%. On a GAAP basis, earnings per share are anticipated to be $5.05-$5.35, indicating a 9-4% decline from the year-ago period. The company notes that adjusted earnings per share will exclude long-term investments in digital capabilities and productivity enhancements to provide greater visibility to the underlying operating performance.

Key Stocks to Consider

Albertsons Companies, Inc. ACI has an expected long-term earnings growth rate of 12% and it currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Duckhorn Portfolio NAPA has an expected long-term earnings growth rate of 9.4% and a Zacks Rank #2 (Buy) at present.

Helen of Troy HELE, also a Zacks Rank #2 stock, has an expected long-term earnings growth rate of 8%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Albertsons Companies, Inc. (ACI) : Free Stock Analysis Report

The Clorox Company (CLX) : Free Stock Analysis Report

Helen of Troy Limited (HELE) : Free Stock Analysis Report

The Duckhorn Portfolio, Inc. (NAPA) : Free Stock Analysis Report

To read this article on Zacks.com click here.